The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma

Cancer Science

Volumn 102, Issue 1, 2011, Pages 64-70

  Ramos, Angelita S ^a   Parise, Carolina B ^a   Travassos, Luiz R ^a   Han, Sang W ^a   De Campos Lima, Pedro O ^b   De Moraes, Jane Z ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTIIDIOTYPIC MONOCLONAL ANTIBODY; GANGLIOSIDE GD3; GROWTH INHIBITOR; IDIOTYPIC ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MONOCLONA ANTIBODY 4.E8; MONOCLONAL ANTIBODY 1.F3; MONOCLONAL ANTIBODY 2.C6; MONOCLONAL ANTIBODY 2.G11; MONOCLONAL ANTIBODY 3.A5; MONOCLONAL ANTIBODY 3.B7; MONOCLONAL ANTIBODY 4.B2; MONOCLONAL ANTIBODY 4.C3; MONOCLONAL ANTIBODY 5.C12; MONOCLONAL ANTIBODY 5.C3; MONOCLONAL ANTIBODY 5.D11; MONOCLONAL ANTIBODY 5.E3; MONOCLONAL ANTIBODY 5.G8; MONOCLONAL ANTIBODY 5.H9; MONOCLONAL ANTIBODY R24; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPETITIVE INHIBITION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; FEMALE; GANGLIOSIDES; HUMANS; IMMUNIZATION; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 78650182856     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01771.x     Document Type: Article

References (60)

1. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 147-66.
2. Zhang S, Helling F, Lloyd KO, Livingston PO. Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 1995; 40: 88-94.
3. Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 1996; 43: 152-7.
4. Ragupathi G, Gathuru J, Livingston PO. Antibody inducing polyvalent cancer vaccines. Cancer Treat Res 2005; 123: 157-80.
5. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 1982; 155: 1133-47.
6. Norihisa Y, McVicar DW, Ghosh P et al. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface gangliosides (GD3). J Immunol 1994; 152: 485-95.
7. Triozzi PL, Shah JJ, Wang WQ et al. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. Cancer Biother Radiopharm 2006; 21: 553-60.
8. Welt S, Carswell E, Vogel C-W, Oettgen HF, Old LJ. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialogangliosides GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 1987; 45: 214-29.
9. Houghton AN, Mintzer D, Cordon-Cardo C. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside. A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 1985; 82: 1242-6.
10. Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res 1997; 7 (Suppl 2): S155-62.
11. Iglesias-Bartolomé R, Crespo PM, Gomez GA, Daniotti JL. The antibody to GD3 ganglioside, R24, is rapidly endocytosed and recycled to the plasma membrane via the endocytic recycling compartment. FEBS J 2006; 273: 1744-58.
12. Dippold W, Bernhard H, Meyer zum Buschenfelde KH. Immunological response to intratecal and systemic treatment with ganglioside antibody R24 in patients with malignant melanoma. Eur J Caner 1994; 30A: 137-44.
13. Kirkwood JM, Mascari RA, Edington HD et al. Analysis of therapeutic and immunological effects of R24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 2000; 88: 2693-702.
14. Scott AM, Lee F-T, Hopkins W et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol, 2001; 19: 3976-87.
15. Souza AR, Gesztesi J-L, Moraes JZ, Cruz CRB, Mariano M, Lopes JD. Evidence of idiotypic modulation in the immune response to gp43, the major antigenic component of Paracoccidioides bransiliensis in both mice and humans. Clin Exp Immunol 1998; 114: 40-8.
16. Shearer MH, Dalgleish AG, Chanh TC, Kennedy RC. Idiotype cascades associated with the CD4-HIV glycoprotein 120 interaction: immunization with anti-idiotypic antibodies induces anti-anti-idiotypic responses with anti-CD4 specificity and in vitro neutralizing activity. AIDS Res Hum Retroviruses 2000; 16: 77-86.
17. Vani J, Nayak R, Shaila MS. Immunization of mice with DNA coding for the variable regions of anti-idiotypic antibody generates antigen-specific response. Vaccine 2007; 25: 4922-30.
18. Chang CC, Hernandez-Guzman FG, Luo W, Wang X, Ferrone S, Ghosh D. Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem 2005; 280: 41546-52.
19. Neninger E, Díaz RM, de la Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6: 145-50.
20. Hernández AM, Toledo D, Martínez D et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181: 6625-34.
21. Pal S, Saha A, Mohanty K et al. Generation of Her-2/neu vaccine utilizing idiotypic network cascade. Cancer Biol Ther 2007; 6: 1916-25.
22. Sabbatini P, Dupont J, Aghajanian C et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006; 12: 5503-10.
23. Mohanty K, Saha A, Pal S et al. Anti-tumor immunity by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Res Treat 2007; 104: 1-11.
24. Reinartz S, Kohler S, Schlebusch H et al. Vaccination of patients with advanced ovarian carcinoma with anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004; 10: 1580-7.
25. Lee G, Ge B. Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunol Immunother 2010; 59: 1347-56.
26. Pfisterer J, du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006; 17: 1568-77.
27. Basak S, Birebent B, Purev E et al. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother 2003; 52: 145-54.
28. Pignatari GC, Takeshita D, Parise CB, Soares FA, de Moraes JZ, Han SW. Carcinoembryonic antigen (CEA) mimicry by an anti-idiotypic scFv isolated from anti-Id 6.C4 hybridoma. J Biotechnol 2007; 127: 615-25.
29. Moraes JZ, Carneiro CRW, Buchegger F, Mach J-P, Lopes JD. Induction of an immune response through the idiotypic network with monoclonal anti-idiotype antibodies in the carcinoembrionic antigen system. J Cell Biochem 1992; 50: 324-35.
30. Moraes JZ, Geztesi J-L, Wastermann P, leDussal J-M, Lopes JD, Mach J-P. Anti-idiotypic monoclonal antibody AB3, reacting with the primary antigen (CEA), can localize human colon-carcinoma xenografts as efficiently as AB1. Int J Cancer 1994; 57: 586-91.
31. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
32. St.Groth S, Scheidegger D. Production of monoclonal antibodies: strategies and tactics. J Immunol Methods 1980; 35: 1001-11.
33. Coligan JE, Kruisbbek AM, Margulies DH, Shevach EM, Strober W. Current Protocols in Immunology. New York: John Wiley & Sons, Inc., 1994.
34. Gorelik E, Xu F, Henion T, Anaraki F, Galili U. Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose(alfa)1-2-galactose after alfa1, 2-fucosyltranferase cDNA transfection. Cancer Res 1997; 57: 332-6.
35. Jackson RJ, Engelman RW, Coppola D, Cantor AB, Wharton W, Pledger WJ. p21cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res 2003; 63: 3021-5.
36. Spicer AP, Rowse GJ, Linder TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995; 270: 30093-101.
37. Burlingham WJ, Jankowska-Gan E, DeVito-Haynes L et al. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies. J Immunol 1998; 161: 6705-14.
38. Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol 2005; 174: 2132-42.
39. Portoukalian J, David MJ, Shen X, Richard M, Dubreuil C. Tumor size-dependent elevations of serum gangliosides in patients with head and neck carcinomas. Biochem Int 1989; 18: 759-65.
40. Hakomori S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 1981; 50: 733-64.
41. Hakomori S. Structure and function of glycosphingolipids in transmembrane signalling and cell-cell interactions. Biochem Soc Trans 1993; 21: 583-95.
42. Soiffer RJ, Chapman PB, Murray C et al. Administration of R24 monoclonal antibody and low-dose interleukin-2 for malignant melanoma. Clin Cancer Res 1997; 3: 17-24.
43. Choi BS, Sondel PM, Hank JA et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother 2006; 55: 761-74.
44. Ando S, Yu RK, Scarsdale JN, Kusunoki S, Prestegard JH. High resolution proton NMR studies of gangliosides. Structure of two types of GD3 lactones and their reactivity with monoclonal antibody R24. J Biol Chem 1989; 264: 3478-83.
45. Chapman PB, Gillies SD, Houghton AN, Reilly RM. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody. Cancer Immunol Immunother 1994; 39: 198-204.
46. Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer. J Clin Oncol 2005; 23: 6854-64.
47. Bottomley A, Debruyne C, Felip E et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 2008; 44: 2178-84.
48. Kaminski MJ, MacKenzie CR, Mooibroek MJ et al. The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. J Biol Chem 1999; 274: 5597-604.
49. Ritter G, Ritter-Boosfeld E, Adluri R et al. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer 1995; 62: 668-72.
50. Tai T, Kawashima I, Furukawa K, Lloyd KO. Monoclonal antibody R24 distinguishes between different N-acetyl- and N-glycolylneuraminic acid derivatives of ganglioside GD3. Arch Biochem Biophys 1988; 60: 51-5.
51. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Köhler H. Murine monoclonal antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990; 145: 2758-65.
52. Yang H, Chen ZJ, Kageshita T, Yamada M, Ferrone S. Idiotypic cascate in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies. Eur J Immunol 1993; 23: 1671-7.
53. Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest 1991; 88: 186-92.
54. Yao T-J, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999; 5: 77-81.
55. Chapman PB, Williams L, Salibi N, Hwu W-J, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 2004; 22: 2904-9.
56. Chapman PB, Wu D, Ragupathi G et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 2004; 10: 4717-23.
57. Grey HM, Hirst JW, Cohan MJ. A new mouse immunoglobulin: IgG3. J Exp Med 1971; 133: 289-304.
58. Natsume A, In M, Takamura H et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68: 3863-72.
59. Duah NO, Weiss HA, Jepson A, Tetteh KK, Whittle HC, Conway DJ. Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigens. PLoS ONE 2009; 4 (10): e7381.
60. Akiyoshi DE, Sheoran AS, Rich CM, Richard L, Chapman-Bonofiglio S, Tzipori S. Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against shiga toxin 2. Infect Immun 2010; 78: 1376-82.